Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples